4D Molecular Therapeutics Inc (FDMT) — Cash Flow Reinvestment Rate
4D Molecular Therapeutics Inc (FDMT) has a Cash Flow Reinvestment Rate of 4.54x as of December 2025, reinvesting $129.55 Million (capex $631.00K plus investments $-128.92 Million) from operating cash flow of $28.55 Million. See FDMT free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
4D Molecular Therapeutics Inc Cash Flow Reinvestment Rate (2017–2017)
Historical reinvestment intensity for 4D Molecular Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see FDMT cash flow metrics.
Annual Cash Flow Reinvestment Rate for 4D Molecular Therapeutics Inc (2017–2017)
Year-by-year capital reinvestment analysis for 4D Molecular Therapeutics Inc. See FDMT free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2017 | 1.07x | $8.80 Million | $8.24 Million | $573.00K | — |